Global Meningococcal Disease Vaccine Market Growth 2026-2032
The global Meningococcal Disease Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Meningococcal Disease Vaccine Industry Forecast? looks at past sales and reviews total world Meningococcal Disease Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Meningococcal Disease Vaccine sales for 2026 through 2032. With Meningococcal Disease Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Meningococcal Disease Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Meningococcal Disease Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Meningococcal Disease Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Meningococcal Disease Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Meningococcal Disease Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Meningococcal Disease Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Meningococcal Disease Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Meningococcal Disease Vaccine Industry Forecast? looks at past sales and reviews total world Meningococcal Disease Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Meningococcal Disease Vaccine sales for 2026 through 2032. With Meningococcal Disease Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Meningococcal Disease Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Meningococcal Disease Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Meningococcal Disease Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Meningococcal Disease Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Meningococcal Disease Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Meningococcal Disease Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Meningococcal Disease Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Polysaccharide
- Conjugate
- Combination
- Infant
- Child
- Aldult
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca
- Johnson & Johnson
- Mylan N.V
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc
- GlaxoSmithKline plc
- Novartis AG
- Sanofi
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Baxter
- BIO-MED
- Bio-Manguinhos
- Walvax Biotechnology Co., Ltd
- What is the 10-year outlook for the global Meningococcal Disease Vaccine market?
- What factors are driving Meningococcal Disease Vaccine market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Meningococcal Disease Vaccine market opportunities vary by end market size?
- How does Meningococcal Disease Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Meningococcal Disease Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Meningococcal Disease Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Meningococcal Disease Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Meningococcal Disease Vaccine Segment by Type
2.2.1 Polysaccharide
2.2.2 Conjugate
2.2.3 Combination
2.2.4 Meningococcal Disease Vaccine Sales by Type
2.2.4.1 Global Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
2.2.4.2 Global Meningococcal Disease Vaccine Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Meningococcal Disease Vaccine Sale Price by Type (2021-2026)
2.3 Meningococcal Disease Vaccine Segment by Application
2.3.1 Infant
2.3.2 Child
2.3.3 Aldult
2.3.4 Meningococcal Disease Vaccine Sales by Application
2.3.4.1 Global Meningococcal Disease Vaccine Sale Market Share by Application (2021-2026)
2.3.4.2 Global Meningococcal Disease Vaccine Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Meningococcal Disease Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Meningococcal Disease Vaccine Breakdown Data by Company
3.1.1 Global Meningococcal Disease Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Meningococcal Disease Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Meningococcal Disease Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Meningococcal Disease Vaccine Revenue by Company (2021-2026)
3.2.2 Global Meningococcal Disease Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Meningococcal Disease Vaccine Sale Price by Company
3.4 Key Manufacturers Meningococcal Disease Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Meningococcal Disease Vaccine Product Location Distribution
3.4.2 Players Meningococcal Disease Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MENINGOCOCCAL DISEASE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Meningococcal Disease Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Meningococcal Disease Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Meningococcal Disease Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Meningococcal Disease Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Meningococcal Disease Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Meningococcal Disease Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Meningococcal Disease Vaccine Sales Growth
4.4 APAC Meningococcal Disease Vaccine Sales Growth
4.5 Europe Meningococcal Disease Vaccine Sales Growth
4.6 Middle East & Africa Meningococcal Disease Vaccine Sales Growth
5 AMERICAS
5.1 Americas Meningococcal Disease Vaccine Sales by Country
5.1.1 Americas Meningococcal Disease Vaccine Sales by Country (2021-2026)
5.1.2 Americas Meningococcal Disease Vaccine Revenue by Country (2021-2026)
5.2 Americas Meningococcal Disease Vaccine Sales by Type (2021-2026)
5.3 Americas Meningococcal Disease Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Meningococcal Disease Vaccine Sales by Region
6.1.1 APAC Meningococcal Disease Vaccine Sales by Region (2021-2026)
6.1.2 APAC Meningococcal Disease Vaccine Revenue by Region (2021-2026)
6.2 APAC Meningococcal Disease Vaccine Sales by Type (2021-2026)
6.3 APAC Meningococcal Disease Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Meningococcal Disease Vaccine by Country
7.1.1 Europe Meningococcal Disease Vaccine Sales by Country (2021-2026)
7.1.2 Europe Meningococcal Disease Vaccine Revenue by Country (2021-2026)
7.2 Europe Meningococcal Disease Vaccine Sales by Type (2021-2026)
7.3 Europe Meningococcal Disease Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Meningococcal Disease Vaccine by Country
8.1.1 Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Meningococcal Disease Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Meningococcal Disease Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Meningococcal Disease Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Meningococcal Disease Vaccine
10.3 Manufacturing Process Analysis of Meningococcal Disease Vaccine
10.4 Industry Chain Structure of Meningococcal Disease Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Meningococcal Disease Vaccine Distributors
11.3 Meningococcal Disease Vaccine Customer
12 WORLD FORECAST REVIEW FOR MENINGOCOCCAL DISEASE VACCINE BY GEOGRAPHIC REGION
12.1 Global Meningococcal Disease Vaccine Market Size Forecast by Region
12.1.1 Global Meningococcal Disease Vaccine Forecast by Region (2027-2032)
12.1.2 Global Meningococcal Disease Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Meningococcal Disease Vaccine Forecast by Type (2027-2032)
12.7 Global Meningococcal Disease Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Meningococcal Disease Vaccine Product Portfolios and Specifications
13.1.3 AstraZeneca Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Meningococcal Disease Vaccine Product Portfolios and Specifications
13.2.3 Johnson & Johnson Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Mylan N.V
13.3.1 Mylan N.V Company Information
13.3.2 Mylan N.V Meningococcal Disease Vaccine Product Portfolios and Specifications
13.3.3 Mylan N.V Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Mylan N.V Main Business Overview
13.3.5 Mylan N.V Latest Developments
13.4 Teva Pharmaceutical Industries Ltd
13.4.1 Teva Pharmaceutical Industries Ltd Company Information
13.4.2 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.4.3 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.4.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.5 Pfizer Inc
13.5.1 Pfizer Inc Company Information
13.5.2 Pfizer Inc Meningococcal Disease Vaccine Product Portfolios and Specifications
13.5.3 Pfizer Inc Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Pfizer Inc Main Business Overview
13.5.5 Pfizer Inc Latest Developments
13.6 GlaxoSmithKline plc
13.6.1 GlaxoSmithKline plc Company Information
13.6.2 GlaxoSmithKline plc Meningococcal Disease Vaccine Product Portfolios and Specifications
13.6.3 GlaxoSmithKline plc Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 GlaxoSmithKline plc Main Business Overview
13.6.5 GlaxoSmithKline plc Latest Developments
13.7 Novartis AG
13.7.1 Novartis AG Company Information
13.7.2 Novartis AG Meningococcal Disease Vaccine Product Portfolios and Specifications
13.7.3 Novartis AG Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Novartis AG Main Business Overview
13.7.5 Novartis AG Latest Developments
13.8 Sanofi
13.8.1 Sanofi Company Information
13.8.2 Sanofi Meningococcal Disease Vaccine Product Portfolios and Specifications
13.8.3 Sanofi Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Sanofi Main Business Overview
13.8.5 Sanofi Latest Developments
13.9 Merck & Co., Inc.
13.9.1 Merck & Co., Inc. Company Information
13.9.2 Merck & Co., Inc. Meningococcal Disease Vaccine Product Portfolios and Specifications
13.9.3 Merck & Co., Inc. Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Merck & Co., Inc. Main Business Overview
13.9.5 Merck & Co., Inc. Latest Developments
13.10 F. Hoffmann-La Roche Ltd
13.10.1 F. Hoffmann-La Roche Ltd Company Information
13.10.2 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.10.3 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.10.5 F. Hoffmann-La Roche Ltd Latest Developments
13.11 Baxter
13.11.1 Baxter Company Information
13.11.2 Baxter Meningococcal Disease Vaccine Product Portfolios and Specifications
13.11.3 Baxter Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Baxter Main Business Overview
13.11.5 Baxter Latest Developments
13.12 BIO-MED
13.12.1 BIO-MED Company Information
13.12.2 BIO-MED Meningococcal Disease Vaccine Product Portfolios and Specifications
13.12.3 BIO-MED Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 BIO-MED Main Business Overview
13.12.5 BIO-MED Latest Developments
13.13 Bio-Manguinhos
13.13.1 Bio-Manguinhos Company Information
13.13.2 Bio-Manguinhos Meningococcal Disease Vaccine Product Portfolios and Specifications
13.13.3 Bio-Manguinhos Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Bio-Manguinhos Main Business Overview
13.13.5 Bio-Manguinhos Latest Developments
13.14 Walvax Biotechnology Co., Ltd
13.14.1 Walvax Biotechnology Co., Ltd Company Information
13.14.2 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.14.3 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Walvax Biotechnology Co., Ltd Main Business Overview
13.14.5 Walvax Biotechnology Co., Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Meningococcal Disease Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Meningococcal Disease Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Meningococcal Disease Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Meningococcal Disease Vaccine Segment by Type
2.2.1 Polysaccharide
2.2.2 Conjugate
2.2.3 Combination
2.2.4 Meningococcal Disease Vaccine Sales by Type
2.2.4.1 Global Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
2.2.4.2 Global Meningococcal Disease Vaccine Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Meningococcal Disease Vaccine Sale Price by Type (2021-2026)
2.3 Meningococcal Disease Vaccine Segment by Application
2.3.1 Infant
2.3.2 Child
2.3.3 Aldult
2.3.4 Meningococcal Disease Vaccine Sales by Application
2.3.4.1 Global Meningococcal Disease Vaccine Sale Market Share by Application (2021-2026)
2.3.4.2 Global Meningococcal Disease Vaccine Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Meningococcal Disease Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Meningococcal Disease Vaccine Breakdown Data by Company
3.1.1 Global Meningococcal Disease Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Meningococcal Disease Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Meningococcal Disease Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Meningococcal Disease Vaccine Revenue by Company (2021-2026)
3.2.2 Global Meningococcal Disease Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Meningococcal Disease Vaccine Sale Price by Company
3.4 Key Manufacturers Meningococcal Disease Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Meningococcal Disease Vaccine Product Location Distribution
3.4.2 Players Meningococcal Disease Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MENINGOCOCCAL DISEASE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Meningococcal Disease Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Meningococcal Disease Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Meningococcal Disease Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Meningococcal Disease Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Meningococcal Disease Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Meningococcal Disease Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Meningococcal Disease Vaccine Sales Growth
4.4 APAC Meningococcal Disease Vaccine Sales Growth
4.5 Europe Meningococcal Disease Vaccine Sales Growth
4.6 Middle East & Africa Meningococcal Disease Vaccine Sales Growth
5 AMERICAS
5.1 Americas Meningococcal Disease Vaccine Sales by Country
5.1.1 Americas Meningococcal Disease Vaccine Sales by Country (2021-2026)
5.1.2 Americas Meningococcal Disease Vaccine Revenue by Country (2021-2026)
5.2 Americas Meningococcal Disease Vaccine Sales by Type (2021-2026)
5.3 Americas Meningococcal Disease Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Meningococcal Disease Vaccine Sales by Region
6.1.1 APAC Meningococcal Disease Vaccine Sales by Region (2021-2026)
6.1.2 APAC Meningococcal Disease Vaccine Revenue by Region (2021-2026)
6.2 APAC Meningococcal Disease Vaccine Sales by Type (2021-2026)
6.3 APAC Meningococcal Disease Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Meningococcal Disease Vaccine by Country
7.1.1 Europe Meningococcal Disease Vaccine Sales by Country (2021-2026)
7.1.2 Europe Meningococcal Disease Vaccine Revenue by Country (2021-2026)
7.2 Europe Meningococcal Disease Vaccine Sales by Type (2021-2026)
7.3 Europe Meningococcal Disease Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Meningococcal Disease Vaccine by Country
8.1.1 Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Meningococcal Disease Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Meningococcal Disease Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Meningococcal Disease Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Meningococcal Disease Vaccine
10.3 Manufacturing Process Analysis of Meningococcal Disease Vaccine
10.4 Industry Chain Structure of Meningococcal Disease Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Meningococcal Disease Vaccine Distributors
11.3 Meningococcal Disease Vaccine Customer
12 WORLD FORECAST REVIEW FOR MENINGOCOCCAL DISEASE VACCINE BY GEOGRAPHIC REGION
12.1 Global Meningococcal Disease Vaccine Market Size Forecast by Region
12.1.1 Global Meningococcal Disease Vaccine Forecast by Region (2027-2032)
12.1.2 Global Meningococcal Disease Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Meningococcal Disease Vaccine Forecast by Type (2027-2032)
12.7 Global Meningococcal Disease Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Meningococcal Disease Vaccine Product Portfolios and Specifications
13.1.3 AstraZeneca Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Meningococcal Disease Vaccine Product Portfolios and Specifications
13.2.3 Johnson & Johnson Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Mylan N.V
13.3.1 Mylan N.V Company Information
13.3.2 Mylan N.V Meningococcal Disease Vaccine Product Portfolios and Specifications
13.3.3 Mylan N.V Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Mylan N.V Main Business Overview
13.3.5 Mylan N.V Latest Developments
13.4 Teva Pharmaceutical Industries Ltd
13.4.1 Teva Pharmaceutical Industries Ltd Company Information
13.4.2 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.4.3 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.4.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.5 Pfizer Inc
13.5.1 Pfizer Inc Company Information
13.5.2 Pfizer Inc Meningococcal Disease Vaccine Product Portfolios and Specifications
13.5.3 Pfizer Inc Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Pfizer Inc Main Business Overview
13.5.5 Pfizer Inc Latest Developments
13.6 GlaxoSmithKline plc
13.6.1 GlaxoSmithKline plc Company Information
13.6.2 GlaxoSmithKline plc Meningococcal Disease Vaccine Product Portfolios and Specifications
13.6.3 GlaxoSmithKline plc Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 GlaxoSmithKline plc Main Business Overview
13.6.5 GlaxoSmithKline plc Latest Developments
13.7 Novartis AG
13.7.1 Novartis AG Company Information
13.7.2 Novartis AG Meningococcal Disease Vaccine Product Portfolios and Specifications
13.7.3 Novartis AG Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Novartis AG Main Business Overview
13.7.5 Novartis AG Latest Developments
13.8 Sanofi
13.8.1 Sanofi Company Information
13.8.2 Sanofi Meningococcal Disease Vaccine Product Portfolios and Specifications
13.8.3 Sanofi Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Sanofi Main Business Overview
13.8.5 Sanofi Latest Developments
13.9 Merck & Co., Inc.
13.9.1 Merck & Co., Inc. Company Information
13.9.2 Merck & Co., Inc. Meningococcal Disease Vaccine Product Portfolios and Specifications
13.9.3 Merck & Co., Inc. Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Merck & Co., Inc. Main Business Overview
13.9.5 Merck & Co., Inc. Latest Developments
13.10 F. Hoffmann-La Roche Ltd
13.10.1 F. Hoffmann-La Roche Ltd Company Information
13.10.2 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.10.3 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.10.5 F. Hoffmann-La Roche Ltd Latest Developments
13.11 Baxter
13.11.1 Baxter Company Information
13.11.2 Baxter Meningococcal Disease Vaccine Product Portfolios and Specifications
13.11.3 Baxter Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Baxter Main Business Overview
13.11.5 Baxter Latest Developments
13.12 BIO-MED
13.12.1 BIO-MED Company Information
13.12.2 BIO-MED Meningococcal Disease Vaccine Product Portfolios and Specifications
13.12.3 BIO-MED Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 BIO-MED Main Business Overview
13.12.5 BIO-MED Latest Developments
13.13 Bio-Manguinhos
13.13.1 Bio-Manguinhos Company Information
13.13.2 Bio-Manguinhos Meningococcal Disease Vaccine Product Portfolios and Specifications
13.13.3 Bio-Manguinhos Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Bio-Manguinhos Main Business Overview
13.13.5 Bio-Manguinhos Latest Developments
13.14 Walvax Biotechnology Co., Ltd
13.14.1 Walvax Biotechnology Co., Ltd Company Information
13.14.2 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.14.3 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Walvax Biotechnology Co., Ltd Main Business Overview
13.14.5 Walvax Biotechnology Co., Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Meningococcal Disease Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Meningococcal Disease Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Polysaccharide
Table 4. Major Players of Conjugate
Table 5. Major Players of Combination
Table 6. Global Meningococcal Disease Vaccine Sales by Type (2021-2026) & (K Units)
Table 7. Global Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
Table 8. Global Meningococcal Disease Vaccine Revenue by Type (2021-2026) & ($ million)
Table 9. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2021-2026)
Table 10. Global Meningococcal Disease Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Meningococcal Disease Vaccine Sale by Application (2021-2026) & (K Units)
Table 12. Global Meningococcal Disease Vaccine Sale Market Share by Application (2021-2026)
Table 13. Global Meningococcal Disease Vaccine Revenue by Application (2021-2026) & ($ million)
Table 14. Global Meningococcal Disease Vaccine Revenue Market Share by Application (2021-2026)
Table 15. Global Meningococcal Disease Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Meningococcal Disease Vaccine Sales by Company (2021-2026) & (K Units)
Table 17. Global Meningococcal Disease Vaccine Sales Market Share by Company (2021-2026)
Table 18. Global Meningococcal Disease Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Meningococcal Disease Vaccine Revenue Market Share by Company (2021-2026)
Table 20. Global Meningococcal Disease Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Meningococcal Disease Vaccine Producing Area Distribution and Sales Area
Table 22. Players Meningococcal Disease Vaccine Products Offered
Table 23. Meningococcal Disease Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Meningococcal Disease Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Meningococcal Disease Vaccine Sales Market Share Geographic Region (2021-2026)
Table 28. Global Meningococcal Disease Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Meningococcal Disease Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Meningococcal Disease Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Meningococcal Disease Vaccine Sales Market Share by Country/Region (2021-2026)
Table 32. Global Meningococcal Disease Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Meningococcal Disease Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Meningococcal Disease Vaccine Sales by Country (2021-2026) & (K Units)
Table 35. Americas Meningococcal Disease Vaccine Sales Market Share by Country (2021-2026)
Table 36. Americas Meningococcal Disease Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Meningococcal Disease Vaccine Sales by Type (2021-2026) & (K Units)
Table 38. Americas Meningococcal Disease Vaccine Sales by Application (2021-2026) & (K Units)
Table 39. APAC Meningococcal Disease Vaccine Sales by Region (2021-2026) & (K Units)
Table 40. APAC Meningococcal Disease Vaccine Sales Market Share by Region (2021-2026)
Table 41. APAC Meningococcal Disease Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Meningococcal Disease Vaccine Sales by Type (2021-2026) & (K Units)
Table 43. APAC Meningococcal Disease Vaccine Sales by Application (2021-2026) & (K Units)
Table 44. Europe Meningococcal Disease Vaccine Sales by Country (2021-2026) & (K Units)
Table 45. Europe Meningococcal Disease Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Meningococcal Disease Vaccine Sales by Type (2021-2026) & (K Units)
Table 47. Europe Meningococcal Disease Vaccine Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Meningococcal Disease Vaccine Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Meningococcal Disease Vaccine Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Meningococcal Disease Vaccine Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Meningococcal Disease Vaccine
Table 53. Key Market Challenges & Risks of Meningococcal Disease Vaccine
Table 54. Key Industry Trends of Meningococcal Disease Vaccine
Table 55. Meningococcal Disease Vaccine Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Meningococcal Disease Vaccine Distributors List
Table 58. Meningococcal Disease Vaccine Customer List
Table 59. Global Meningococcal Disease Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Meningococcal Disease Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Meningococcal Disease Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Meningococcal Disease Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Meningococcal Disease Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Meningococcal Disease Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Meningococcal Disease Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Meningococcal Disease Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Meningococcal Disease Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Meningococcal Disease Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Meningococcal Disease Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Meningococcal Disease Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Meningococcal Disease Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Meningococcal Disease Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. AstraZeneca Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 74. AstraZeneca Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 75. AstraZeneca Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. AstraZeneca Main Business
Table 77. AstraZeneca Latest Developments
Table 78. Johnson & Johnson Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Johnson & Johnson Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 80. Johnson & Johnson Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Johnson & Johnson Main Business
Table 82. Johnson & Johnson Latest Developments
Table 83. Mylan N.V Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. Mylan N.V Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 85. Mylan N.V Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Mylan N.V Main Business
Table 87. Mylan N.V Latest Developments
Table 88. Teva Pharmaceutical Industries Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 90. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Teva Pharmaceutical Industries Ltd Main Business
Table 92. Teva Pharmaceutical Industries Ltd Latest Developments
Table 93. Pfizer Inc Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Inc Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 95. Pfizer Inc Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Pfizer Inc Main Business
Table 97. Pfizer Inc Latest Developments
Table 98. GlaxoSmithKline plc Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. GlaxoSmithKline plc Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 100. GlaxoSmithKline plc Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. GlaxoSmithKline plc Main Business
Table 102. GlaxoSmithKline plc Latest Developments
Table 103. Novartis AG Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Novartis AG Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 105. Novartis AG Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Novartis AG Main Business
Table 107. Novartis AG Latest Developments
Table 108. Sanofi Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Sanofi Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 110. Sanofi Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Sanofi Main Business
Table 112. Sanofi Latest Developments
Table 113. Merck & Co., Inc. Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Merck & Co., Inc. Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 115. Merck & Co., Inc. Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Merck & Co., Inc. Main Business
Table 117. Merck & Co., Inc. Latest Developments
Table 118. F. Hoffmann-La Roche Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 120. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. F. Hoffmann-La Roche Ltd Main Business
Table 122. F. Hoffmann-La Roche Ltd Latest Developments
Table 123. Baxter Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Baxter Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 125. Baxter Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Baxter Main Business
Table 127. Baxter Latest Developments
Table 128. BIO-MED Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. BIO-MED Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 130. BIO-MED Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. BIO-MED Main Business
Table 132. BIO-MED Latest Developments
Table 133. Bio-Manguinhos Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. Bio-Manguinhos Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 135. Bio-Manguinhos Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Bio-Manguinhos Main Business
Table 137. Bio-Manguinhos Latest Developments
Table 138. Walvax Biotechnology Co., Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 139. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 140. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Walvax Biotechnology Co., Ltd Main Business
Table 142. Walvax Biotechnology Co., Ltd Latest Developments
Table 1. Meningococcal Disease Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Meningococcal Disease Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Polysaccharide
Table 4. Major Players of Conjugate
Table 5. Major Players of Combination
Table 6. Global Meningococcal Disease Vaccine Sales by Type (2021-2026) & (K Units)
Table 7. Global Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
Table 8. Global Meningococcal Disease Vaccine Revenue by Type (2021-2026) & ($ million)
Table 9. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2021-2026)
Table 10. Global Meningococcal Disease Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Meningococcal Disease Vaccine Sale by Application (2021-2026) & (K Units)
Table 12. Global Meningococcal Disease Vaccine Sale Market Share by Application (2021-2026)
Table 13. Global Meningococcal Disease Vaccine Revenue by Application (2021-2026) & ($ million)
Table 14. Global Meningococcal Disease Vaccine Revenue Market Share by Application (2021-2026)
Table 15. Global Meningococcal Disease Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Meningococcal Disease Vaccine Sales by Company (2021-2026) & (K Units)
Table 17. Global Meningococcal Disease Vaccine Sales Market Share by Company (2021-2026)
Table 18. Global Meningococcal Disease Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Meningococcal Disease Vaccine Revenue Market Share by Company (2021-2026)
Table 20. Global Meningococcal Disease Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Meningococcal Disease Vaccine Producing Area Distribution and Sales Area
Table 22. Players Meningococcal Disease Vaccine Products Offered
Table 23. Meningococcal Disease Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Meningococcal Disease Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Meningococcal Disease Vaccine Sales Market Share Geographic Region (2021-2026)
Table 28. Global Meningococcal Disease Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Meningococcal Disease Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Meningococcal Disease Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Meningococcal Disease Vaccine Sales Market Share by Country/Region (2021-2026)
Table 32. Global Meningococcal Disease Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Meningococcal Disease Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Meningococcal Disease Vaccine Sales by Country (2021-2026) & (K Units)
Table 35. Americas Meningococcal Disease Vaccine Sales Market Share by Country (2021-2026)
Table 36. Americas Meningococcal Disease Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Meningococcal Disease Vaccine Sales by Type (2021-2026) & (K Units)
Table 38. Americas Meningococcal Disease Vaccine Sales by Application (2021-2026) & (K Units)
Table 39. APAC Meningococcal Disease Vaccine Sales by Region (2021-2026) & (K Units)
Table 40. APAC Meningococcal Disease Vaccine Sales Market Share by Region (2021-2026)
Table 41. APAC Meningococcal Disease Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Meningococcal Disease Vaccine Sales by Type (2021-2026) & (K Units)
Table 43. APAC Meningococcal Disease Vaccine Sales by Application (2021-2026) & (K Units)
Table 44. Europe Meningococcal Disease Vaccine Sales by Country (2021-2026) & (K Units)
Table 45. Europe Meningococcal Disease Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Meningococcal Disease Vaccine Sales by Type (2021-2026) & (K Units)
Table 47. Europe Meningococcal Disease Vaccine Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Meningococcal Disease Vaccine Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Meningococcal Disease Vaccine Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Meningococcal Disease Vaccine Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Meningococcal Disease Vaccine
Table 53. Key Market Challenges & Risks of Meningococcal Disease Vaccine
Table 54. Key Industry Trends of Meningococcal Disease Vaccine
Table 55. Meningococcal Disease Vaccine Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Meningococcal Disease Vaccine Distributors List
Table 58. Meningococcal Disease Vaccine Customer List
Table 59. Global Meningococcal Disease Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Meningococcal Disease Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Meningococcal Disease Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Meningococcal Disease Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Meningococcal Disease Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Meningococcal Disease Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Meningococcal Disease Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Meningococcal Disease Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Meningococcal Disease Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Meningococcal Disease Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Meningococcal Disease Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Meningococcal Disease Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Meningococcal Disease Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Meningococcal Disease Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. AstraZeneca Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 74. AstraZeneca Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 75. AstraZeneca Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. AstraZeneca Main Business
Table 77. AstraZeneca Latest Developments
Table 78. Johnson & Johnson Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Johnson & Johnson Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 80. Johnson & Johnson Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Johnson & Johnson Main Business
Table 82. Johnson & Johnson Latest Developments
Table 83. Mylan N.V Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. Mylan N.V Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 85. Mylan N.V Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Mylan N.V Main Business
Table 87. Mylan N.V Latest Developments
Table 88. Teva Pharmaceutical Industries Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 90. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Teva Pharmaceutical Industries Ltd Main Business
Table 92. Teva Pharmaceutical Industries Ltd Latest Developments
Table 93. Pfizer Inc Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Inc Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 95. Pfizer Inc Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Pfizer Inc Main Business
Table 97. Pfizer Inc Latest Developments
Table 98. GlaxoSmithKline plc Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. GlaxoSmithKline plc Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 100. GlaxoSmithKline plc Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. GlaxoSmithKline plc Main Business
Table 102. GlaxoSmithKline plc Latest Developments
Table 103. Novartis AG Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Novartis AG Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 105. Novartis AG Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Novartis AG Main Business
Table 107. Novartis AG Latest Developments
Table 108. Sanofi Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Sanofi Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 110. Sanofi Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Sanofi Main Business
Table 112. Sanofi Latest Developments
Table 113. Merck & Co., Inc. Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Merck & Co., Inc. Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 115. Merck & Co., Inc. Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Merck & Co., Inc. Main Business
Table 117. Merck & Co., Inc. Latest Developments
Table 118. F. Hoffmann-La Roche Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 120. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. F. Hoffmann-La Roche Ltd Main Business
Table 122. F. Hoffmann-La Roche Ltd Latest Developments
Table 123. Baxter Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Baxter Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 125. Baxter Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Baxter Main Business
Table 127. Baxter Latest Developments
Table 128. BIO-MED Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. BIO-MED Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 130. BIO-MED Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. BIO-MED Main Business
Table 132. BIO-MED Latest Developments
Table 133. Bio-Manguinhos Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. Bio-Manguinhos Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 135. Bio-Manguinhos Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Bio-Manguinhos Main Business
Table 137. Bio-Manguinhos Latest Developments
Table 138. Walvax Biotechnology Co., Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 139. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 140. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Walvax Biotechnology Co., Ltd Main Business
Table 142. Walvax Biotechnology Co., Ltd Latest Developments
LIST OF FIGURES
Figure 1. Picture of Meningococcal Disease Vaccine
Figure 2. Meningococcal Disease Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Meningococcal Disease Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Meningococcal Disease Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Meningococcal Disease Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Meningococcal Disease Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Meningococcal Disease Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Polysaccharide
Figure 12. Product Picture of Conjugate
Figure 13. Product Picture of Combination
Figure 14. Global Meningococcal Disease Vaccine Sales Market Share by Type in 2026
Figure 15. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2021-2026)
Figure 16. Meningococcal Disease Vaccine Consumed in Infant
Figure 17. Global Meningococcal Disease Vaccine Market: Infant (2021-2026) & (K Units)
Figure 18. Meningococcal Disease Vaccine Consumed in Child
Figure 19. Global Meningococcal Disease Vaccine Market: Child (2021-2026) & (K Units)
Figure 20. Meningococcal Disease Vaccine Consumed in Aldult
Figure 21. Global Meningococcal Disease Vaccine Market: Aldult (2021-2026) & (K Units)
Figure 22. Global Meningococcal Disease Vaccine Sale Market Share by Application (2025)
Figure 23. Global Meningococcal Disease Vaccine Revenue Market Share by Application in 2026
Figure 24. Meningococcal Disease Vaccine Sales by Company in 2026 (K Units)
Figure 25. Global Meningococcal Disease Vaccine Sales Market Share by Company in 2026
Figure 26. Meningococcal Disease Vaccine Revenue by Company in 2026 ($ millions)
Figure 27. Global Meningococcal Disease Vaccine Revenue Market Share by Company in 2026
Figure 28. Global Meningococcal Disease Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Meningococcal Disease Vaccine Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Meningococcal Disease Vaccine Sales 2021-2026 (K Units)
Figure 31. Americas Meningococcal Disease Vaccine Revenue 2021-2026 ($ millions)
Figure 32. APAC Meningococcal Disease Vaccine Sales 2021-2026 (K Units)
Figure 33. APAC Meningococcal Disease Vaccine Revenue 2021-2026 ($ millions)
Figure 34. Europe Meningococcal Disease Vaccine Sales 2021-2026 (K Units)
Figure 35. Europe Meningococcal Disease Vaccine Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Meningococcal Disease Vaccine Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Meningococcal Disease Vaccine Revenue 2021-2026 ($ millions)
Figure 38. Americas Meningococcal Disease Vaccine Sales Market Share by Country in 2026
Figure 39. Americas Meningococcal Disease Vaccine Revenue Market Share by Country (2021-2026)
Figure 40. Americas Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
Figure 41. Americas Meningococcal Disease Vaccine Sales Market Share by Application (2021-2026)
Figure 42. United States Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Meningococcal Disease Vaccine Sales Market Share by Region in 2026
Figure 47. APAC Meningococcal Disease Vaccine Revenue Market Share by Region (2021-2026)
Figure 48. APAC Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
Figure 49. APAC Meningococcal Disease Vaccine Sales Market Share by Application (2021-2026)
Figure 50. China Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. India Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Meningococcal Disease Vaccine Sales Market Share by Country in 2026
Figure 58. Europe Meningococcal Disease Vaccine Revenue Market Share by Country (2021-2026)
Figure 59. Europe Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
Figure 60. Europe Meningococcal Disease Vaccine Sales Market Share by Application (2021-2026)
Figure 61. Germany Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. France Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Application (2021-2026)
Figure 69. Egypt Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Meningococcal Disease Vaccine in 2026
Figure 75. Manufacturing Process Analysis of Meningococcal Disease Vaccine
Figure 76. Industry Chain Structure of Meningococcal Disease Vaccine
Figure 77. Channels of Distribution
Figure 78. Global Meningococcal Disease Vaccine Sales Market Forecast by Region (2027-2032)
Figure 79. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Meningococcal Disease Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Meningococcal Disease Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Meningococcal Disease Vaccine
Figure 2. Meningococcal Disease Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Meningococcal Disease Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Meningococcal Disease Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Meningococcal Disease Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Meningococcal Disease Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Meningococcal Disease Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Polysaccharide
Figure 12. Product Picture of Conjugate
Figure 13. Product Picture of Combination
Figure 14. Global Meningococcal Disease Vaccine Sales Market Share by Type in 2026
Figure 15. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2021-2026)
Figure 16. Meningococcal Disease Vaccine Consumed in Infant
Figure 17. Global Meningococcal Disease Vaccine Market: Infant (2021-2026) & (K Units)
Figure 18. Meningococcal Disease Vaccine Consumed in Child
Figure 19. Global Meningococcal Disease Vaccine Market: Child (2021-2026) & (K Units)
Figure 20. Meningococcal Disease Vaccine Consumed in Aldult
Figure 21. Global Meningococcal Disease Vaccine Market: Aldult (2021-2026) & (K Units)
Figure 22. Global Meningococcal Disease Vaccine Sale Market Share by Application (2025)
Figure 23. Global Meningococcal Disease Vaccine Revenue Market Share by Application in 2026
Figure 24. Meningococcal Disease Vaccine Sales by Company in 2026 (K Units)
Figure 25. Global Meningococcal Disease Vaccine Sales Market Share by Company in 2026
Figure 26. Meningococcal Disease Vaccine Revenue by Company in 2026 ($ millions)
Figure 27. Global Meningococcal Disease Vaccine Revenue Market Share by Company in 2026
Figure 28. Global Meningococcal Disease Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Meningococcal Disease Vaccine Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Meningococcal Disease Vaccine Sales 2021-2026 (K Units)
Figure 31. Americas Meningococcal Disease Vaccine Revenue 2021-2026 ($ millions)
Figure 32. APAC Meningococcal Disease Vaccine Sales 2021-2026 (K Units)
Figure 33. APAC Meningococcal Disease Vaccine Revenue 2021-2026 ($ millions)
Figure 34. Europe Meningococcal Disease Vaccine Sales 2021-2026 (K Units)
Figure 35. Europe Meningococcal Disease Vaccine Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Meningococcal Disease Vaccine Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Meningococcal Disease Vaccine Revenue 2021-2026 ($ millions)
Figure 38. Americas Meningococcal Disease Vaccine Sales Market Share by Country in 2026
Figure 39. Americas Meningococcal Disease Vaccine Revenue Market Share by Country (2021-2026)
Figure 40. Americas Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
Figure 41. Americas Meningococcal Disease Vaccine Sales Market Share by Application (2021-2026)
Figure 42. United States Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Meningococcal Disease Vaccine Sales Market Share by Region in 2026
Figure 47. APAC Meningococcal Disease Vaccine Revenue Market Share by Region (2021-2026)
Figure 48. APAC Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
Figure 49. APAC Meningococcal Disease Vaccine Sales Market Share by Application (2021-2026)
Figure 50. China Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. India Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Meningococcal Disease Vaccine Sales Market Share by Country in 2026
Figure 58. Europe Meningococcal Disease Vaccine Revenue Market Share by Country (2021-2026)
Figure 59. Europe Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
Figure 60. Europe Meningococcal Disease Vaccine Sales Market Share by Application (2021-2026)
Figure 61. Germany Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. France Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Application (2021-2026)
Figure 69. Egypt Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Meningococcal Disease Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Meningococcal Disease Vaccine in 2026
Figure 75. Manufacturing Process Analysis of Meningococcal Disease Vaccine
Figure 76. Industry Chain Structure of Meningococcal Disease Vaccine
Figure 77. Channels of Distribution
Figure 78. Global Meningococcal Disease Vaccine Sales Market Forecast by Region (2027-2032)
Figure 79. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Meningococcal Disease Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Meningococcal Disease Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Application (2027-2032)
